GSK-3β as a target for protection against transient cerebral ischemia

Wei Wang1,2*, Mingchang Li1*, Yuefei Wang1, Zhongyu Wang3,4, Wei Zhang4, Fangxia Guan5, Qianxue Chen1**, Jian Wang3,6**

1. Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, P.R. China; 2. Department of Traumatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P.R. China; 3. Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 4. Department of Anesthesiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450082, P.R. China; 5. School of Life Sciences, Zhengzhou University, Zhengzhou 450000, P.R. China; 6. Department of Anatomy, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China

* These authors contributed equally to the manuscript.

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Abstract

Stroke remains the leading cause of death and disability worldwide. This fact highlights the need to search for potential drug targets that can reduce stroke-related brain damage. We showed recently that a glycogen synthase kinase-3β (GSK-3β) inhibitor attenuates tissue plasminogen activator-induced hemorrhagic transformation after permanent focal cerebral ischemia. Here, we examined whether GSK-3β inhibition mitigates early ischemia-reperfusion stroke injury and investigated its potential mechanism of action. We used the rat middle cerebral artery occlusion (MCAO) model to mimic transient cerebral ischemia. At 3.5 h after MCAO, cerebral blood flow was restored, and rats were administered DMSO (vehicle, 1% in saline) or GSK-3β inhibitor TWS119 (30 mg/kg) by intraperitoneal injection. Animals were sacrificed 24 h after MCAO. TWS119 treatment reduced neurologic deficits, brain edema, and blood-brain barrier permeability compared with those in the vehicle group. TWS119 treatment also increased the protein expression of β-catenin and zonula occludens-1 but decreased β-catenin phosphorylation while suppressing the expression of GSK-3β. These results indicate that GSK-3β inhibition protects the blood-brain barrier and attenuates early ischemia-reperfusion stroke injury. This protection may be related to early activation of the Wnt/β-catenin signaling pathway.

Key words: blood-brain barrier; ischemic stroke; Wnt/β-catenin signaling; TWS119

Introduction

Stroke is a leading cause of death and disability worldwide. Thus, identifying potential new drug targets is critical to developing therapies that will reduce stroke-related brain damage. It is known that early disruption of the blood-brain barrier (BBB) contributes to acute cerebral ischemia-reperfusion injury1. In recent years, new strategies, such as delayed inhibition of VEGF signaling2, and new drug candidates, such as a novel analog of ginkgolide B (XQ-1H)3 a novel adhesion molecule CEACAM14, orosomucoid5, and lavandula officinalis ethanolic extract6, have been tested for their potential to protect the BBB in ischemic stroke models. Because the results from these studies have been promising, increasing attention is turning toward the identification of potential drug targets to protect the BBB after ischemic stroke.

The Wnt/β-catenin signaling pathway is involved in development of the BBB7, and its dysfunction could lead to BBB breakdown in
Alzheimer’s disease. Furthermore, activation of Wnt/β-catenin signaling enhances neurogenesis and improves neurologic function after focal ischemic injury. However, the role of the Wnt/β-catenin signaling pathway in BBB breakdown and its effects on stroke outcomes are unknown.

Studies have shown that the serine-threonine kinase glycogen synthase kinase-3β (GSK-3β) is involved in the phosphorylation and degradation of β-catenin, the key molecule of the Wnt/β-catenin pathway. Therefore, inhibition of GSK-3β may increase the level of β-catenin and further activate the Wnt/β-catenin signaling pathway. TWS119, a 4,6-disubstituted pyrrolo-pyrimidine, is a potent inhibitor of GSK-3β. We have recently shown that TWS119 attenuates tissue plasminogen activator (tPA)-induced hemorrhagic transformation after permanent middle cerebral artery occlusion (MCAO).

In the present study, we used a rat model of transient MCAO to mimic the clinical scenario of acute ischemic stroke, and administered TWS119 to activate the Wnt/β-catenin signaling pathway. We hypothesized that GSK-3β inhibition would protect the BBB and reduce early ischemia-reperfusion stroke injury.

Materials and Methods

Animals

All protocols used in this study were approved by the Institutional Animal Care and Use Committee at Wuhan University. Adult male Sprague-Dawley rats weighing 250–280 g were purchased from Wuhan University Center for Animal Experiments and housed under standard conditions with a 12:12 h light/dark cycle. Food and water were provided to all animals ad libitum. The operators were blinded to the treatment status of the animals in all experiments.

MCAO Model

Focal cerebral ischemia was produced by endovascular occlusion of the left middle cerebral artery (MCA) as described previously. Briefly, rats were anesthetized by intraperitoneal injection with pentobarbital sodium (Dainippon Sumitomo Pharma, Osaka, Japan). Body temperature was maintained at 36.5°C to 37.5°C throughout surgery. After a midline neck incision, the left common carotid artery (CCA) was isolated under a microscope and ligated with a 4-0 silk suture (Ethicon, Issy-Les-Moulineaux, France). The external and internal carotid arteries were temporarily ligated with a 4-0 silk suture. An arteriotomy was performed proximal to the bifurcation of the CCA. A silicone-coated nylon monofilament (40 mm long, 0.26 mm diameter, Beijing Sunbio Biotech, China) was introduced through the arteriotomy and advanced into the internal carotid artery up to a distance of 18–20 mm to occlude the origin of the MCA. At 3.5 hours after this procedure, the rats were reanesthetized, the nylon monofilament was withdrawn to restore MCA blood flow, and TWS119 (30 mg/kg in 1% dimethyl sulfoxide, Selleck, Houston, TX, USA) or an equal volume of vehicle (DMSO) was administered. After surgery, the rats were returned to their home cages with free access to food and water. A third group of sham control rats underwent the same surgical procedure but the monofilament was not inserted and they were administered only DMSO.

Neurologic Deficit Score

An investigator blinded to the experimental groups performed a neurologic examination of the rats at 24 h after MCAO using a modified version of the scoring system developed by Longa. Rats were anesthetized and killed by decapitation at 24 h after MCAO. The brains were quickly removed and placed on a dry surface. A 4-mm-thick section of the frontal pole was dissected free before the brain was cut by a brain slicer (Beijing Sunny Instruments Co., Ltd., Beijing, China) and divided into the ipsilateral and contralateral hemispheres. The two hemisphere slices were packaged in preweighed aluminum foil and immediately weighed on an electronic balance to obtain the wet weight. The hemispheres were then dried for 24 h in an oven at 100°C and reweighed to obtain the dry weight. Brain water content was calculated as a percentage with the following formula: (wet weight − dry weight)/wet weight × 100%

Brain Infarct Volume

Infarct volume after MCAO was determined by 2, 3, 5-triphenyltetrazolium chloride (TTC, Sigma, Santa Clara, CA) at 24 h after MCAO. Animals were euthanized, and the brains were quickly collected. Brain tissue was sliced into seven coronal sections (2-mm thick) and stained with a 2% solution of TTC at 37°C for 20 min, followed by fixation with 4% paraformaldehyde. TTC stains normal tissue red, but the infarct area remains a pale gray color. TTC-stained
sections were photographed, and ImageJ image-processing software was used to calculate the infarct volume. The ratio of infarct volume = infarct area of the ipsilateral hemisphere/total area of the ipsilateral hemisphere × 100%22.

**Evaluation of BBB Permeability**

Evans blue (EB) dye (2%, 3 ml/kg, Sigma) was administered intravenously 3 h before the brain was collected. After being perfused with saline, each hemisphere was weighed and homogenized in 4 ml of 50% trichloroacetic acid solution. The homogenates were centrifuged at 10,000×g for 30 min, and the supernatants were collected and diluted with ethanol (1:3). EB content was determined on a spectrophotometer (Epoch™&Take3™, Biotek, USA) at 620 nm and calculated from a standard curve of EB. EB extravasation was expressed as EB extravasation index (EBI): the ratio of absorbance intensity in the ischemic hemisphere to that in the nonischemic hemisphere23.

**Western Blotting**

Based on our established protocol24, 25, the total protein were prepared using Cytoplasmic and Nuclear Protein Extraction Kit (Feremants, Shanghai, China) and equal amounts of total protein were separated by Tris-glycine SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% skim milk and then incubated with the following primary antibodies overnight at 4°C: (1) rabbit polyclonal anti-GAPDH antibody (1:1000, Cell Signaling Technology, Danvers, MA, USA); (2) rabbit polyclonal anti-β-catenin antibody (1:5000, Abcam, Cambridge, MA, USA); (3) rabbit polyclonal anti-phosphorylated β-catenin (Ser 552) antibody (1:1000, Cell Signaling Technology, Cambridge, MA, USA); (4) mouse polyclonal anti-GSK-3β antibody (1:1000, Cell Signaling Technology); (5) rabbit polyclonal anti-zonula adhacludens-1 (ZO-1) antibody (1:100, Santa Cruz Biotechnology, Dallas, TX, USA). After incubation with the secondary antibody (1:1000, Cell Signaling Technology) for 2 h, membranes were washed three times with phosphate-buffered saline (10 min each), and the relative density of bands was analyzed on an Odyssey infrared scanner (LICOR Bioscience, Lincoln, NE, USA).

**Statistical Analysis**

All data are expressed as mean ± SD. SPSS for Windows 16.0 software package was used to analyze the data. Differences among groups were determined by one-way ANOVA followed by Tukey post-hoc tests. Student's t-test was used to compare the difference between two groups. Differences were considered significant at P values less than 0.05.

**Results**

**Mortality Rates**

Mortality was 0% (0/24) in the sham group, 12.5% (3/24) in the vehicle group, and 4.2% (1/24) in the TWS119 group. Mortality rate was not significantly different among the three groups (P > 0.05).

**GSK-3β Inhibition by TWS119 Improved Neurologic Function, Cerebral Edema, and Infarction Volume After Transient MCAO**

Neurologic deficit, brain water content, and infarct volume were evaluated 24 h after MCAO. TWS119 significantly reduced the neurologic deficit scores compared with those in the vehicle group (n=24 rats/group, P < 0.05; Fig. 1.A). No neurologic deficit was observed in the sham group (data not shown). Similarly, brain water content was lower and infarct volume was smaller in the TWS119-treated group than in the vehicle-treated group (n=6 rats/group, both P<0.05; Figs. 1.B and 2), suggesting that GSK-3β inhibition attenuates brain edema and infarct volume after transient MCAO. The sham group exhibited no cerebral edema or infarction.

![Figure 1](http://www.medsci.org)

Figure 1. A. Neurologic deficit score at 24 h after transient middle cerebral artery occlusion (MCAO). Rats were treated with vehicle or TWS119 (n=24 rats/group). The data are expressed as means ± SD. *P<0.05 vs. vehicle group. B. Brain water content at 24 h after transient middle cerebral artery occlusion (MCAO). The data are expressed as means ± SD. *P<0.05, **P<0.01 vs. sham group.
GSK-3β Inhibition by TWS119 Decreased BBB Permeability After Transient MCAO

In our study, EB dye leakage was concentrated mainly in the regions of ischemic hemisphere, and BBB leakage was shown with the EBI. We found that EBI of the TWS119-treated group was significantly lower than that of the vehicle-treated group (n=6 rats/group, P<0.05; Fig. 3), indicating that GSK-3β inhibition protects the BBB after transient MCAO.

GSK-3β Inhibition by TWS119 Activated the Wnt/β-Catenin Signaling Pathway and Increased the Expression of ZO-1 After Transient MCAO

Western blot quantification showed that the total protein expression of β-catenin was upregulated, whereas phosphorylated β-catenin (p-β-catenin) and GSK-3β expression were downregulated in the TWS119-treated group compared with that in the vehicle-treated group (n=6 rats/group, P<0.05; Fig. 4). And the ratio of p-β-catenin to the total β-catenin was reduced significantly after TWS119 treatment (n=6 rats/group, P<0.05; Fig. 4). Additionally, the expression of ZO-1 was significantly higher in the TWS119-treated group than in the vehicle-treated group (n=6 rats/group, P<0.05; Fig. 4). These data indicate that GSK-3β inhibition by TWS119 might activate the Wnt/β-catenin signaling pathway, which is associated with increased ZO-1 expression and attenuated BBB disruption.

Discussion

In this study, GSK-3β inhibition by TWS119 reduced neurologic deficit score, brain edema, infarct volume, and BBB disruption. This protection was associated with an early activation of Wnt/β-catenin signaling and an increase in ZO-1 expression. Together, these findings suggest that GSK-3β inhibition by TWS119 attenuates early ischemia-reperfusion injury and protects the BBB.
Ischemic stroke remains a significant health problem worldwide. Previous studies have shown that thioredoxin, anfibatide, and inhibition of CD36-mediated inflammation mitigate ischemic stroke injury. Recently, Luo et al. demonstrated that interleukin-33 ameliorates ischemic brain injury by promoting Th2 response and suppressing Th17 response. Nicotinamide mononucleotide adenyllytransferase 1 is another molecule that has exhibited potential neuroprotective effects in vitro and in vivo models of cerebral ischemia. We have recently shown that GSK-3β inhibitor TWS119 with reported dose and treatment regimen attenuates tPA-induced hemorrhagic transformation after permanent focal cerebral ischemia. Here, we showed that TWS119 reduced early ischemia-reperfusion injury and protected the BBB.

Although many efforts have been made to attenuate ischemic stroke injury, there is no effective therapy that can be used clinically to protect the BBB. The BBB is a key factor that affects acute stroke outcome and should be targeted for protection. The European Cooperative Acute Stroke Study (ECASS)-3 has shown that rtPA alteplase has a safe therapeutic window of 3-4.5 h after the onset of stroke symptoms. Therefore, in our study, we administered TWS119 at 3.5 h after MCAO and found that it reduced the permeability of the BBB. This finding suggests that TWS119 has a protective effect on the BBB after ischemic stroke, and GSK-3β could be a potential target for brain protection, which was consistent with other studies.

Previous studies have demonstrated the role of the Wnt/β-catenin signaling pathway in the brain's vascular development and BBB formation. Dickkopf-1, a negative modulator of the Wnt pathway, is involved in the development of ischemic neuronal death. Growing evidence indicates that Wnt signaling protects the BBB in several brain diseases. However, the relationship between Wnt/β-catenin signaling and BBB integrity in acute ischemic stroke is still unclear.

To elucidate the underlying mechanisms of action of TWS119, we examined the expression of key proteins in the Wnt/β-catenin pathway as well as tight junction protein ZO-1 at 24 h after MCAO. While suppressing the expression of GSK-3β, TWS119 inhibited phosphorylation of β-catenin and increased...
its total protein expression. β-catenin is a key component for activating the Wnt/β-catenin pathway, and phosphorylation at Ser522 has been shown to induce β-catenin accumulation in the nucleus and increases its transcriptional activity. However, other studies found that the Ser-552 phosphorylation site did not seem important for modulation of β-catenin transcriptional activity. In our study, we found that β-catenin was upregulated, whereas GSK-3β and p-β-catenin were downregulated in the TWS119-treated group compared with levels in the vehicle-treated group, indicating that TWS119 may activate the Wnt/β-catenin pathway by inhibiting GSK-3β expression, reducing p-β-catenin, and enhancing β-catenin expression. The tight junction protein ZO-1 participates in the maintenance of BBB integrity and is the major transmembranal protein of tight junctions in the BBB. ZO-1 controls angiogenesis and barrier formation. However, whether Wnt/β-catenin signaling can regulate ZO-1 expression after BBB disruption in ischemic stroke is unknown. Our results showed that in the TWS119-treated group, a reduction in BBB permeability was associated with activation of Wnt/β-catenin signaling and upregulation of ZO-1 expression. The sequence of the signaling may need additional research in both in vitro and in vivo models of the BBB.

In summary, our study showed that GSK-3β inhibition with TWS119 protected the BBB and attenuated early ischemia-reperfusion stroke injury. This protection may be related to an early activation of the Wnt/β-catenin signaling pathway and an increase in ZO-1 expression. Thus, the activation of Wnt/β-catenin signaling has potential to protect the BBB after ischemic stroke. However, the specific mechanism needs additional research.

Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (81171112, 81371272 to M.C.L., 81372683 to Q.X.C.) and grants from the National Institutes of Health (R01NS078026, R01AT007317 to J.W.).

Competing Interests
The authors have declared that no competing interest exists.

References
1. Takeuchi S, Nagatani K, Otani N, Nawashiro H, Sugawara T, Wada K, et al. Hydrogen improves neurological function through attenuation of blood-brain barrier disruption in spontaneously hypertensive stroke-prone rats. BMC Neurosci. 2015;16:22.
2. Reeson F, Tennant KA, Gerrow K, Wang J, Weiser Novak S, Thompson K, et al. Delayed inhibition of VEGF signaling after stroke attenuates blood-brain barrier breakdown and improves functional recovery in a comorbidity-dependent manner. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013;35:5128-43.
3. Fang W, Sha L, Kodithuwakku ND, Wei J, Zhang R, Han D, et al. Attenuated Blood-Brain Barrier Dysfunction by XQ-1H Following Ischemic Stroke in Hyperlipidemic Rats. Molecular neurobiology. 2015;52:162-75.
4. Weiner GM, Ducruet AF. CEACAM1: a novel adhesion molecule that regulates the secretion of matrix metalloproteinase-9 in neutrophils and protects the blood-brain barrier after ischemic stroke. Neurosurgery. 2014;75:N21-2.
5. Wu L, Jiang Y, Zhu J, Wen Z, Xu X, Xu X, et al. Oromucoid II: Involved in vascular endothelial growth factor-induced blood-brain barrier leakage after ischemic stroke in mouse. Brain research bulletin. 2014;108:88-96.
6. Rabiei Z, Rafieian-Kopaei M. Neuroprotective effect of pretreatment with Lavandula officinalis ethanol extract on blood-brain barrier permeability in a rat stroke model. Asian Pacific journal of tropical medicine. 2014;7:8421-6.
7. Lieberwirth S, Corada M, Barbaro T, Bhupathy J, Taddie A, Czupalla CJ, et al. Wnt/beta-catenin signaling controls development of the blood-brain barrier. The Journal of cell biology. 2008;183:409-17.
8. Liu L, Wan W, Xia S, Kalenius B, Li Y. Dysfunctional Wnt/beta-catenin signaling contributes to blood-brain barrier breakdown in Alzheimer's disease. Neurochemistry international. 2014;75:19-25.
9. Shruster A, Ben-Zur T, Melamed E, Offen D. Wnt signaling enhances neurogenesis and improves neurological function after focal ischemic injury. Stroke. 2012;43:8483.
10. Ding S, Wu TY, Brinker A, Peters EC, Haur W, Gray NS, et al. Synthetic small molecules that control stem cell fate. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:7632-7.
11. Chen Y, Zheng L, Liu J, Zhou Z, Lv X, Zhang J, et al. [Activation of Wnt/beta-catenin pathway in NK cells by glycogen synthase kinase-beta inhibitor TWS119 promotes the expression of CDE6L.] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. 2015;31:448.
12. Wang W, Li M, Chen Q, Wang J. Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers. Molecular neurobiology. 2015;52:1572-9.
13. Wang W, Li M, Wang Y, Li Q, Deng G, Wan J, et al. GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/beta-catenin signaling pathway after acute ischemic stroke in rats. Molecular neurobiology. 2016;53:7028-36.
14. Zan L, Zhang X, Xi Y, Wu H, Song X, Teng G, et al. Src regulates angiogenic factors and vascular permeability after focal cerebral ischemia-reperfusion. Neuroscience. 2014;262:118-28.
15. Li Y, Xu XL, Zhao D, Pan LN, Huang CW, Guo LJ, et al. TL83 ligand Poly IC Attenuates Reactive Astrogliosis and Improves Recovery of Rats after Focal Cerebral Ischemia. CNS neuroscience & therapeutics. 2015;21:905-13.
16. Wang M, Hong X, Chang CF, Li Q, Ma B, Zhang H, et al. Simultaneous detection and separation of hyperacetylated intracerebral hemorrhage and cerebral ischemia using amide proton transfer MRI. Magnetic resonance in medicine. 2015.
17. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15:808-13.
18. Wang W, Li M, Wang Y, Li Q, Deng G, Wan J, et al. GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/beta-catenin signaling pathway after acute ischemic stroke in rats. Molecular neurobiology. 2015.
19. Wang J, Yu L, Jiang C, Chen M, Ou C, Wang J. Bone marrow mononuclear cells exert long-term neuroprotection in a rat model of ischemic stroke by promoting arteriogenesis and angiogenesis. Brain, behavior, and immunity. 2013;34:56-66.
20. Zan L, Wu H, Jiang J, Zhao S, Song Y, Teng G, et al. Temporal profile of Src, S6KCS, and angiogenic factors after focal cerebral ischemia: correlations with angiogenesis and cerebral edema. Neurochemistry international. 2015;87:2-9.
21. Zhao X, Wu T, Chang CF, Wu H, Han X, Li Q, et al. Toxic role of prostaglandin E2 receptor EP1 after intracerebral hemorrhage in mice. Brain, behavior, and immunity. 2015;46:293-310.
22. Wang J, Liu X, Lu H, Jiang C, Cui X, Yu L, et al. CXCR4(+)/CD45(-) BMMNC subpopulation is superior to unfractionated BMMNCs for protection after ischemic stroke in mice. Brain, behavior, and immunity. 2015;45:98-108.
23. Zhang W, Davis CM, Edin ML, Lee CR, Zeldin DC, Alkayed NJ. Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury. PloS one. 2013;8:e61244.
24. Wang J, Yu L, Jiang C, Hao T, Zhao L, Zhang X, et al. CXCR4(+)CD45(-) BMMNCs enhance regenerative responses and promote angiogenesis in the ischemic brain. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013;34:196-208.
25. Wang J, Yin L, Jiang C, Hao T, Zhao L, Zhang X, et al. Intraperitoneal administration of thioexorose decreases brain damage after cerebral ischemia. Brain research. 2015;1615:89-97.
28. Li TT, Fan ML, Hou SX, Li XY, Barry DM, Jin H, et al. A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury. British journal of pharmacology. 2015;172:3904-16.

29. Kim EH, Tolhurst AT, Szeto HH, Cho SH. Targeting CD36-mediated inflammation reduces acute brain injury in transient, but not permanent, ischemic stroke. CNS neuroscience & therapeutics. 2015;21:385-91.

30. Luo Y, Zhou Y, Xiao W, Liang Z, Dai J, Weng X, et al. Interleukin-33 ameliorates ischemic brain injury in experimental stroke through promoting Th2 response and suppressing Th17 response. Brain research. 2015;1597:86-94.

31. Liang J, Wang P, Wei J, Bao C, Han D. Nicotinamide Mononucleotide Adenylyltransferase 1 Protects Neural Cells Against Ischemic Injury in Primary Cultured Neuronal Cells and Mouse Brain with Ischemic Stroke Through AMP-Activated Protein Kinase Activation. Neurochemical research. 2015;40:1102-10.

32. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. The New England journal of medicine. 2008;359:1317-29.

33. Ajmone-Cat MA, D’Urso MC, di Blasio G, Brignone MS, De Simone R, Minghetti L. Glycogen synthase kinase 3 is part of the molecular machinery regulating the adaptive response to LPS stimulation in microglial cells. Brain, behavior, and immunity. 2016;55:225-35.

34. Lin CF, Tsai CC, Huang WC, Wang YC, Tsen PC, Tsei TT, et al. Glycogen Synthase Kinase-3beta and Caspase-2 Mediate Ceramide- and Etoposide-Induced Apoptosis by Regulating the Lysosomal-Mitochondrial Axis. PloS one. 2016;11:e0145460.

35. Artus C, Glacial F, Ganeshamoorthy K, Ziegler N, Godet M, Guillet B, et al. The Wnt/planar cell polarity signaling pathway contributes to the integrity of tight junctions in brain endothelial cells. J Cereb Blood Flow Metab. 2014;34:433-40.

36. Reis M, Liebner S. Wnt signaling in the vasculature. Experimental cell research. 2013;319:1317-23.

37. Polakis P. Formation of the blood-brain barrier: Wnt signaling seals the deal. The Journal of cell biology. 2008;183:371-3.

38. Zhou J, Chen Y, Cao C, Chen X, Gao W, Zhang L. Inactivation of glycogen synthase kinase-3beta up-regulates beta-catenin and promotes angiogenesis. Cell and tissue banking. 2015;16:133-42.

39. Ji XK, Xie YK, Zhong JQ, Xu QQ, Zeng QQ, Wang Y, et al. GSK-3beta suppresses the proliferation of rat hepatic oval cells through modulating Wnt/beta-catenin signaling pathway. Acta pharmacologica Sinica. 2015;36:334-42.

40. Taurin S, Sandeo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. The Journal of biological chemistry. 2006;281:9971-6.

41. Li Y, Zhu J, Liu Y, Liu X, Lei L, Li L, et al. Glycogen Synthase Kinase 3beta Influences Injury Following Cerebral Ischemia/Reperfusion in Rats. International journal of biological sciences. 2016;12:518-31.

42. Ha TS, Park HY, Seong SB, Ahn HY. Puromycin aminonucleoside increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner. Experimental cell research. 2016;340:139-49.

43. Tornavaca O, Chia M, Dufton N, Almagro LO, Conway DE, Randi AM, et al. ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation. The Journal of cell biology. 2015;208:821-38.